While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed
outcomes of people with rheumatoid arthritis (RA), a proportion of patients are refractory to …

Rheumatoid arthritis (RA) is a highly heterogeneous syndrome in terms of clinical
presentation, progression, and response to therapy. In such a complicated context, the …

Rheumatoid arthritis (RA) is a chronic, systemic immune-mediated inflammatory disease that
can lead to joint destruction, functional disability and substantial comorbidity due to the …

The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway is
an important intracellular route through which many different extracellular soluble …

Recent innovation in high-throughput sequencing technologies has drastically empowered
the scientific research. Consequently, now, it is possible to capture comprehensive profiles …

Modern high-throughput 'omics' science tools (including genomics, transcriptomics,
proteomics, metabolomics and microbiomics) are currently being applied to nutritional …

Advances in understanding of the pathophysiology of rheumatoid arthritis with concurrent
advances in protein engineering led to the development of biological disease-modifying …

Objectives To evaluate real-world efficacy of approved JAK inhibitors (JAKi) tofacitinib and
baricitinib in a large, single-centre cohort of RA patients across the treatment pathway …

In recent years, difficult-to-treat rheumatoid arthritis (D2T RA) has attracted significant
attention from rheumatologists due to its poor treatment response and the persistent …

Rheumatoid arthritis (RA) is a chronic inflammatory and systemic autoimmune disease with
an unknown aetiology. Accumulative studies suggest that the pathogenesis of RA involves …